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Abstract: Allergic rhinitis is a common and often distressing
condition. Currently, treatment with nonsedating antihistamines,
topical therapy, and immunotherapy are very effective. Despite this,
intramuscular depot steroids are commonly used in clinical practice.
Here, we present the case of a young woman who developed
disﬁguring scarring after a depot steroid injection. This case high-
lights the risks of this form of treatment for allergic rhinitis.
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Allergic rhinitis affects up to 20% of the population. Nasalallergies cause considerable misery and are responsible for
many lost days of productivity and nonattendance at school.
Careful history will reveal the typical symptoms associated with
allergic rhinitis. Nasal obstruction is frequently the most dis-
tressing symptom associated with poor quality of sleep.1
Examination shows classical changes in the nasal
mucosa. The seasonal nature of the symptoms will often
assist with the identiﬁcation of the likely triggers. Grass,
weed, and tree pollens are typically seasonal but with
considerable geographic variation. The tree pollen season in
New Zealand, for example, is shorter than that of the northern
hemisphere. These clinical impressions can be conﬁrmed by
skin prick testing or by assay of speciﬁc IgE antibodies to
inhalant allergens.
Currently, most patients can be effectively managed
with a combination of oral or nasal antihistamines and steroid
nose sprays. In recent years, allergen-speciﬁc immunother-
apy, whether given sublingually or by subcutaneous injection,
has proved very effective in the management of allergic
rhinitis.
Patients with unresponsive symptoms may need to be
evaluated for chronic rhinosinusitis. A computed tomography
and rhinoscopy may be useful in delineating nasal and sinus
anatomy. Patients who fail medical therapy or those with
skeletal abnormalities, such as a deviated nasal septum, may
beneﬁt from a surgical procedure such as a turbinectomy or
functional endoscopic sinus surgery.
Systemic steroids have played a role in the management
of allergic rhinitis in the past 5 decades. Early reports
conﬁrmed an excellent response to systemic steroids. In
recent years, the use of oral steroids has not been recom-
mended for the management of allergic rhinitis in view of the
efﬁcacy of topical therapy and concerns about adverse effects.
However, oral and intramuscular depot steroids remain
popular in primary care because of their efﬁcacy and the
expense of allergen-speciﬁc immunotherapy. Here, we present
the case of a patient who suffered disﬁguring subcutaneous
atrophy in the gluteal region from a depot triamcinolone
injection given for allergic rhinitis.
CASE REPORT
The patient is a 29-year-old immigrant. Shortly after
moving to New Zealand, she suffered disabling allergic
rhinitis symptoms. Her symptoms were perennial. She was
clinically assessed by her family physician and was given
a depot 40-mg triamcinolone injection into the gluteal
region. She experienced rapid relief of her nasal obstruction
and rhinorrhea. She had received prior injections of depot
steroids for her rhinitis. Within a few weeks, she developed
a large 5-cm scar at the injection site (Figs. 1 and 2).
She was reviewed in the immunology clinic at the
Auckland Hospital. Skin prick testing conﬁrmed strongly
positive reactions to dust mites. She was treated with a combi-
nation of loratadine 10 mg and Budesonide 100 mg nasal spray
twice daily. She declined the offer of immunotherapy on
account of expense. She was reviewed by a plastics and recon-
structive surgeon, but no operative intervention was offered.
DISCUSSION
Depot steroid injections for seasonal allergic rhinitis
have been commonly used in some parts of the world,
particularly Denmark. One study estimated that 0.66% of
the entire Danish population received depot steroid injections
each year.2
The efﬁcacy of depot steroid injections has been
established in several randomized controlled trials.3 Depot
steroids appear to be more effective than topical beclometha-
sone4 and are as effective as 7.5 mg of oral prednisone given
for 3 weeks.5 Most patients experience 4 to 5 weeks of symp-
toms relief after a single injection.
Generally, nasal obstruction is more likely to improve
than rhinorrhea or sneezing. It is of interest that most of these
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randomized trials of depot steroids were undertaken in
Denmark. All these randomized trials of depot steroids for
allergic rhinitis were undertaken before 1988. It was around
this time that effective nonsedating antihistamines became
widely available.
In recent years, there has been increasing concern about
the use of depot steroids in the management of allergic
rhinitis.6 Patients with severe symptoms unresponsive to anti-
histamines and topical steroid therapy should be referred to an
allergy specialist for consideration of immunotherapy.7 The
lack of allergy services in many parts of the world, including
New Zealand, has hindered such referrals.8
Although relatively uncommon, adverse effects from
depot steroids are a source of increasing concern. Bilateral
avascular necrosis after a depot steroid injection has been
reported.8 There is concern about hypothalamic pituitary
adrenal axis suppression and long-lasting effects on
bone mineral density.6
Subcutaneous atrophy of the deltoid has been described
after depot steroid injections for allergic rhinitis. This has
been termed pseudomorphea.9 One case of subcutaneous atro-
phy has been estimated to occur after 11,000 injections.2
Although this may be a rare event, there is concern about
underreporting.6 In some patients, the area of scarring improves
slowly after several years.
This case illustrates the small but signiﬁcant risk of
using this form of treatment for a non–life-threatening disor-
der. Before this case, it was previously thought that intramus-
cular injections into the gluteal region were associated with
a low risk of subcutaneous atrophy.2 It is uncertain if this
patient received an intramuscular injection or whether the
triamcinolone was injected into the subcutaneous tissues.
Depot steroid injections remain very poplar among
primary care physicians and patients. Their low cost and
effectiveness underscore this popularity. The pressure to use
this form of treatment should be resisted given the small but
signiﬁcant risk of disﬁguring adverse effects.
A short course of oral steroids could be justiﬁed for
patients attending an important function such as a wedding or
before surgery in unresponsive patients. Given the availability
of effective therapy, depot steroid injections should be
considered an obsolete form of treatment for allergic rhinitis.
This from of treatment, particularly repeated doses, should no
longer be accepted as the standard of care of allergic
rhinitis.10
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FIGURE 2. Close-up view of the 5-cm scar after a 40-mg
triamcinolone injection given for allergic rhinitis.
FIGURE 1. Subcutaneous atrophy of the gluteal region after
a 40-mg depot triamcinolone injection.
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